Job description: We pride ourselves on our integrity. We do what’s right for our employees, patients and partners, and so can you. We are currently recruiting for a Talent Acquisition Administrator to join the HR team for a 12-month fixed term contract. Located within the UK the purpose of this role is to provide a comprehensive recruitment administration service to our hiring managers and candidates, as well as, supporting other activities across all aspects of HR. Our Human Resources team provides strategic and operational support across the business with recruitment, learning and development, talent management, employee engagement and internal communication. Your responsibilities in this role would be: Working with the Recruiter, act as first point of contact for all ad hoc recruitment queries and resolve as many as possible without referral. Advise managers and employees on Company policies and procedures to ensure understanding and compliance. Coordinate recruitment administration, including scheduling interviews, production of employment contracts and opening background check cases for our external provider. Administer the company’s Application Tracking System to ensure that it is updated throughout the recruitment process. Support the coordination of onboarding new starters and their induction programme We are looking for: Good basic secondary school education Good practical knowledge of employment law relating to recruitment and selection Microsoft office suite – intermediate user Good experience of high-volume recruitment practices Strong planning and organisation skills is essential A clear communicator both written and orally in English. French would be helpful but not essential Good attention to detail is essential This is a hybrid role, working from our offices in Oxford two days per week About Us: OXB is a quality and innovation-led viral vector CDMO with a mission to enable its clients to deliver life changing therapies to patients around the world. One of the original pioneers in cell and gene therapy, we have more than 25 years of experience in viral vectors; the driving force behind the majority of gene therapies. OXB collaborates with some of the world’s most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV) and adenoviral vectors. OXB’s world-class capabilities span from early-stage development to commercialisation. These capabilities are supported by robust quality-assurance systems, analytical methods, and depth of regulatory expertise. What’s in it for you: Highly competitive total reward packages Wellbeing programmes Development opportunities Welcoming, friendly, supportive colleagues A diverse and inclusive working environment Our values are: Responsible, Responsive, Resilient, Respect State of the art laboratory and manufacturing facilities Collaborate. Contribute. Change lives We offer: Oxford Biomedica is a quality and innovation-led viral vector CDMO that enables its clients to deliver life-changing therapies to patients around the world. One of the original pioneers in cell and gene therapy, Oxford Biomedica has more than 25 years of experience in viral vectors, the driving force behind the majority of gene therapies. Cell and gene therapy is the treatment of disease by the delivery of therapeutic genetic material (DNA or RNA), into a patient’s cells. One highly effective approach to delivering genetic information is to re-engineer existing viruses to be safe delivery vehicles (vectors) to insert the genetic material into patients’ cells. This can be achieved either by directly administering the vector to the patient (often referred to as in vivo gene therapy), or by first introducing the genetic material to cells or tissue outside of the body, before administering the cells or tissue into the patient (often referred to as ex vivo gene therapy or gene-modified cell therapy). Oxford Biomedica collaborates with some of the world's most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV) and adenoviral vectors. Oxford Biomedica's world-class capabilities span from early-stage development to commercialisation. These capabilities are supported by robust quality-assurance systems, analytical methods and depth of regulatory expertise.